EUVIMEDSkopri EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Circular RNAs: Unlocking new avenues in cardiometabolic disease management

Kimberley M Mellor iD, Thomas D Donelly iD, Gerald L M Naepi, Glenn D Wadley iD, Bianca C Bernardo iD

The Journal of Physiology · 2026

DOI: 10.1113/jp289839 ↗

At a glance

Übersichtsarbeit in The Journal of Physiology, 2026. Written by Kimberley M Mellor and 4 co-authors. Institution: Department of Physiology, University of Auckland, Auckland, New Zealand. Major MEDLINE topics: RNA, Circular, Cardiovascular Diseases, Metabolic Diseases. Cited 2 times so far (Crossref); 93 references. The full text is freely available (open access, CC BY 4.0).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Cardiometabolic diseases refer to a group of interrelated conditions that affect both the cardiovascular system and metabolic processes. These conditions represent a significant global health burden and often share common risk factors such as obesity, high cholesterol and insulin resistance. Cardiometabolic diseases include conditions such as hypertension, diabetes, heart failure, coronary artery disease and stroke. Recent advancements in molecular biology have highlighted the pivotal role of circular RNAs (circRNAs) in the regulation of gene expression and cellular processes. These stable, covalently closed RNA molecules act as microRNA sponges, modulating the activity of key metabolic and cardiovascular pathways. This review explores the emerging potential of circRNAs as novel therapeutic targets in cardiometabolic disease, focusing on the mechanisms by which circRNAs influence disease progression, their utility as biomarkers for early diagnosis and prognosis and the innovative therapeutic strategies being developed to harness their regulatory functions. However research into circRNAs also comes with its unique set of challenges, relating to detection, quantification, annotation variability and functional characterisation. Despite these challenges the potential for circRNAs to advance understanding and treatment of disease continues to drive research forward, paving the way for new diagnostic and therapeutic strategies to better manage cardiometabolic diseases. image

Subjects

MeSH terms (MEDLINE)

RNA, CircularCardiovascular DiseasesMetabolic DiseasesHumansAnimalsRNA, Competitive EndogenousBiomarkers

Author keywords

cardiometabolic diseasecircRNAsheart failurenon‐coding RNAstherapeutic targets

Substances

RNA, CircularRNA, Competitive EndogenousBiomarkers

Authors and institutions

  • Department of Physiology, University of Auckland, Auckland, New Zealand.
  • School of Exercise and Nutrition Sciences, Faculty of Health, Deakin University, Melbourne, Victoria, Australia.
  • Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Faculty of Health, Deakin University, Melbourne, Victoria, Australia.
  • Department of Cardiometabolic Health, The University of Melbourne, Melbourne, Victoria, Australia.

ORCID profiles: Kimberley M Mellor, Thomas D Donelly, Glenn D Wadley, Bianca C Bernardo

Cite

APA

Mellor, K. M., Donelly, T. D., Naepi, G. L. M., Wadley, G. D., & Bernardo, B. C. (2026). Circular RNAs: Unlocking new avenues in cardiometabolic disease management. The Journal of Physiology. https://doi.org/10.1113/jp289839

Vancouver

Mellor KM, Donelly TD, Naepi GLM, Wadley GD, Bernardo BC. Circular RNAs: Unlocking new avenues in cardiometabolic disease management. The Journal of Physiology. 2026. doi:10.1113/jp289839

BibTeX
@article{Mellor2026,
  author = {Mellor, Kimberley M and Donelly, Thomas D and Naepi, Gerald L M and Wadley, Glenn D and Bernardo, Bianca C},
  title = {Circular RNAs: Unlocking new avenues in cardiometabolic disease management},
  journal = {The Journal of Physiology},
  year = {2026},
  doi = {10.1113/jp289839}
}
Start for free →